{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:53Z","timestamp":1778284853497,"version":"3.51.4"},"reference-count":57,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,3,10]],"date-time":"2006-03-10T00:00:00Z","timestamp":1141948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2006,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:sc>L<\/jats:sc>\u2010dopa\u2013induced dyskinesia (LID) remains a major complication of the treatment of Parkinson's disease. The neural mechanisms underlying LID are thought to involve overactivity of striatal glutamatergic neurotransmission, with resultant underactivation of the output regions of the basal ganglia. Histamine H3 heteroreceptors can reduce glutamate and \u03b3\u2010aminobutyric acid (GABA) transmission in the striatum and substantia nigra reticulata, respectively. Thus, we tested whether the histamine H3 receptor agonists immepip and imetit can alleviate LID in the MPTP\u2010lesioned marmoset model of Parkinson's disease. Coadministration of immepip (1 mg\/kg) with <jats:sc>L<\/jats:sc>\u2010dopa (15 mg\/kg) was associated with significantly less total dyskinesia than <jats:sc>L<\/jats:sc>\u2010dopa alone. When dyskinesia was separately rated as chorea and dystonia, coadministration of <jats:sc>L<\/jats:sc>\u2010dopa with either immepip or imetit (both 10 mg\/kg) significantly reduced chorea but had no effect on dystonia. The antidyskinetic actions of the H3 agonists were not accompanied by alteration of the antiparkinsonian actions of <jats:sc>L<\/jats:sc>\u2010dopa. However, immepip (10 mg\/kg), when administered as monotherapy, significantly increased parkinsonian disability compared to vehicle. Overall, the results obtained in this study suggest that histamine H3 receptors may be involved in the neural mechanisms underlying <jats:sc>L<\/jats:sc>\u2010dopa\u2013induced dyskinesia in Parkinson's disease. \u00a9 2006 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.20828","type":"journal-article","created":{"date-parts":[[2006,3,10]],"date-time":"2006-03-10T16:48:41Z","timestamp":1142009321000},"page":"839-846","source":"Crossref","is-referenced-by-count":50,"title":["Histamine H3 receptor agonists reduce <scp>L<\/scp>\u2010dopa\u2013induced chorea, but not dystonia, in the MPTP\u2010lesioned nonhuman primate model of Parkinson's disease"],"prefix":"10.1002","volume":"21","author":[{"given":"Jordi","family":"Gomez\u2010Ramirez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom H.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi P.","family":"Visanji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.11.2131"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00028-8"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(73)90091-9"},{"key":"e_1_2_6_5_2","first-page":"309","article-title":"The tropical localization and content of noradrenalin and dopamine (3\u2010hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease","volume":"75","author":"Hornykiewicz O","year":"1963","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0251-7"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)91410-3"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1969.00480160015001"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00029-X"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20296"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390505"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N\u2010methyl\u2010D\u2010aspartate receptor subtype selective antagonists on dyskinesias in levodopa\u2010treated 1\u2010methyl\u20104\u2010phenyl\u2010tetrahydropyridine monkeys","volume":"290","author":"Blanchet PJ","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130507"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1112"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.11.1383"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/35086062"},{"key":"e_1_2_6_17_2","first-page":"720","article-title":"Drugs in development for Parkinson's disease","volume":"5","author":"Johnston TH","year":"2004","journal-title":"Curr Opin Invest Drugs"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130603"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/302832a0"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00144-7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00101-5"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704053"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200001170-00032"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.55.6.1101"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00800-4"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(98)00152-3"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.61.1.239"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.005652"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002109900097"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2004.04.045"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-16-07272.2002"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00135-5"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00100-0"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2690-04.2004"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0022-3565(25)10340-6","article-title":"S\u2010[2\u2010(4\u2010imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist","volume":"263","author":"Garbarg M","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00170155"},{"key":"e_1_2_6_37_2","first-page":"183","article-title":"MPTP\u2010induced parkinsonism in the common marmoset: behavioral and biochemical effects","volume":"45","author":"Jenner P","year":"1987","journal-title":"Adv Neurol"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10289"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130207"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.05.004"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.03.022"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1148"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10464"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10542"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.066191"},{"issue":"4","key":"e_1_2_6_47_2","first-page":"S60","article-title":"Levodopa\u2010induced dyskinesia: a pathological form of striatal synaptic plasticity?","volume":"47","author":"Calabresi P","year":"2000","journal-title":"Ann Neurol"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20006"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2004.04.050"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7362"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2000.00267.x"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2001.0413"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00871.x"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90279-8"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-6618(03)00094-X"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/327117a0"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4886(03)00064-5"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-3010fje"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.20828","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.20828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:41:51Z","timestamp":1760953311000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.20828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6,6]]}},"alternative-id":["10.1002\/mds.20828"],"URL":"https:\/\/doi.org\/10.1002\/mds.20828","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,6]]}}}